Piramal Pharma Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,752Cr
- −0.1% YoY
- +28.6% QoQ
- Net profit
- −₹9Cr
- Q4 FY25: ₹154 Cr
- Margin
- 16.74%
- −3.6 pp YoY
- +7.6 pp QoQ
Guidance rank: #42 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
From Piramal Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 revenue growth expected in the early to mid-teens percentage range across all businesses.
- CDMO business growth anticipated to be healthy due to improved biotech funding, increased RFPs, higher win rates, and a strong pipeline of RFPs at overseas sites.
- CDMO revenue will remain back-weighted to the second half, especially Q4, due to client order timings.
- On-patent commercial manufacturing revenue grew nearly 50% from the prior year, with 15–16 products supplied; expected continued growth with new product launches.
- ADC (Antibody-Drug Conjugates) segment poised to be a meaningful growth driver in FY27-FY28 and beyond with new customers added.
- Consumer Health Care business grew 17% in FY26 and expects continued broad-based growth with premiumization and strategic launches.
2 more points from Piramal Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027.
- The Riverview expansion is largely complete and already serving clients.
- Capex for FY27 is projected at INR 120 million to INR 135 million, largely towards the Lexington expansion.
- Customer-funded capex related to a specific suite is complete; no further spend planned there.
2 more points from Piramal Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Piramal Pharma is seeing a strong pipeline of Requests for Proposals (RFPs) at overseas sites, which, if converted, will help scale revenues and improve operating leverage.
- The company has improved RFP-to-order conversion rates, especially with new customers.
- A healthy order book for FY27 and beyond is expected, which is crucial for medium-term growth.
- They are working on over 155 molecules in development, with 25 in Phase III, representing future on-patent commercial manufacturing opportunities.
2 more points from Piramal Pharma Ltd's call on order book
Create a free account to keep reading this call
Piramal Pharma Ltd — Quarterly revenue & net profit
Piramal Pharma Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,752 | 2,754 | -0.1% | 2,140 | +28.6% |
| Operating profit (EBITDA) | 461 | 561 | -17.9% | 196 | +135.3% |
| Operating margin | 16.74% | 20.37% | -3.6 pp | 9.15% | +7.6 pp |
| Profit before tax | 43 | 273 | -84.2% | -94 | — |
| Net profit (PAT) | -9 | 154 | -105.8% | -136 | — |
| EPS (₹) | -0.07 | 1.16 | -106% | -1.02 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Piramal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Piramal Pharma Ltd Q4 FY26 results?
FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹27,530 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027.
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
